| Trial ID: | L1398 |
| Source ID: | NCT01012414
|
| Associated Drug: |
Paricalcitol
|
| Title: |
Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease
|
| Acronym: |
VINCA-CKD
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01012414/results
|
| Conditions: |
Coronary Artery Disease|Chronic Kidney Disease|Hypovitaminosis D|Secondary Hyperparathyroidism
|
| Interventions: |
DRUG: paricalcitol|DRUG: placebo
|
| Outcome Measures: |
Primary: Change in High Sensitivity-C Reactive Protein (Serum), 1 year | Secondary: Change in Markers of Inflammation Including Interleukin (IL)-1, IL-6, Tumor Necrosis Factor Alpha, Matrix Metalloproteinase (MMP) -9 and Serum Amyloid A, 1 year|Effect on Known Coronary Artery Disease Risk Factors Including Lipids and Blood Pressure., 1 year|Effect on Carotid Intima-media Thickening (CIMT), 1 year
|
| Sponsor/Collaborators: |
Sponsor: Thomas Jefferson University | Collaborators: Abbott
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
10
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2010-01
|
| Completion Date: |
2011-05
|
| Results First Posted: |
2013-11-11
|
| Last Update Posted: |
2014-05-20
|
| Locations: |
Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01012414
|
